Nonetheless, the presence of 500 μM iron (ferric citrate) reduced the cytarabine-induced decrease inBCL2 mRNA (MV4-11: 0.5 μM cytarabine vs 500 μM Fe + 0.5 μM cytarabine,P < 0.01; MOLM-13: 0.5 μM cytarabine vs 500 μM Fe + 0.5 μM cytarabine,P < 0.01) and the increase inBAX mRNA (MV4-11: 0.5 μM cytarabine vs 500 μM Fe + 0.5 μM cytarabine,P < 0.01; MOLM-13: 0.5 μM cytarabine vs 500 μM Fe + 0.5 μM cytarabine,P < 0.05) in TP53 wild-type AML cell lines (Figure 4F,G). The gene discussed is TP53; the disease is acute myeloid leukemia.